Literature DB >> 23934620

Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?

G Gopal Rao1, Deepak Batura.   

Abstract

PURPOSE: To report the incidence of emergency admissions attributable to infective complications of transrectal ultrasound-guided prostate biopsy (TGB) and evaluate appropriateness of antimicrobial prophylaxis.
METHODS: Retrospective cross-sectional study of patients undergoing TGB at the North West London Hospitals in 2009-2011. Demographic information of patients who had emergency admission within 30 days of TGB, length of hospital stay and microbiology results were obtained from the hospital's information system, medical records and laboratory information system. All patients received ciprofloxacin and amikacin prophylaxis.
RESULTS: 1,419 TGB were performed in 1,276 patients. Forty-eight (3.3 %) patients had emergency admissions. Thirty-three (2.3 %) admissions were due to complications from TGB, while 15 (1 %) were for unrelated reasons. 30/33 (90 %, overall 2.1 %) of admissions from TGB complications were due to confirmed infections or systemic inflammatory response syndrome (SIRS). The rest were admitted with urinary retention. Admission rates due to TGB complications and infection/SIRS remained consistent over the 3 years (2009: TGB complications-2 %, TGB infection/SIRS-1.8 %; 2010: TGB complications-2.4 %, TGB infections/SIRS-2.2 %; 2011: TGB complications-2.6 %, TGB infection/SIRS-2.4 %; P > 0.05). All 11 cases with bacteraemia were caused by ciprofloxacin-resistant but amikacin-susceptible E. coli.
CONCLUSIONS: We observed a consistent rate of emergency admissions for complications following TGB; 90 % of these were due to infections. Ciprofloxacin-resistant but amikacin-sensitive E. coli was isolated in all bacteriologically confirmed infections. These results suggest that infective complications of TGB cannot be altogether eliminated despite appropriate antimicrobial prophylaxis. Therefore, additional strategies for reduction in biopsy-related admissions due to infections have to be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934620     DOI: 10.1007/s11255-013-0529-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  31 in total

1.  Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis?

Authors:  D Steensels; K Slabbaert; L De Wever; P Vermeersch; H Van Poppel; J Verhaegen
Journal:  Clin Microbiol Infect       Date:  2011-09-29       Impact factor: 8.067

2.  Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy.

Authors:  Deepak Batura; G Gopal Rao; Peder Bo Nielsen
Journal:  BJU Int       Date:  2010-03-16       Impact factor: 5.588

3.  Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: our experience in North West London.

Authors:  Benedict R S Rogers; Deepak Batura; G Gopal Rao
Journal:  Clin Infect Dis       Date:  2012-10-19       Impact factor: 9.079

4.  Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients.

Authors:  Daniel Portalez; Pierre Mozer; François Cornud; Raphaëlle Renard-Penna; Vincent Misrai; Matthieu Thoulouzan; Bernard Malavaud
Journal:  Eur Urol       Date:  2012-06-27       Impact factor: 20.096

5.  Vertebral osteomyelitis following transrectal ultrasound-guided biopsy of the prostate.

Authors:  Raghav Rajgopal; Yuding Wang; Kenneth J Faber; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

6.  Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy.

Authors:  Michael A Liss; Amy N Peeples; Ellena M Peterson
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

Review 7.  Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.

Authors:  Linda A Bradley; Glenn E Palomaki; Steven Gutman; David Samson; Naomi Aronson
Journal:  J Urol       Date:  2013-03-29       Impact factor: 7.450

Review 8.  Optimising repeat prostate biopsy decisions and procedures.

Authors:  Roger Kirby; John M Fitzpatrick
Journal:  BJU Int       Date:  2011-12-22       Impact factor: 5.588

9.  Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.

Authors:  Brian T Helfand; Stacy Loeb; Qiaoyan Hu; Phillip R Cooper; Kimberly A Roehl; Barry B McGuire; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2013-02-27       Impact factor: 7.450

10.  Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.

Authors:  David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

View more
  4 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance.

Authors:  Iqbal Sahibzada; Deepak Batura; Giles Hellawell
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

3.  Comparison of a combined regimen of fosfomycin and ciprofloxacin with ciprofloxacin alone as antimicrobial prophylaxis for transrectal prostate biopsy in the era of high fluoroquinolone-resistant rectal flora.

Authors:  Do Gyeong Lim; Seung Il Jung; Myung Soo Kim; Ho Seok Chung; Eu Chang Hwang; Dong Deuk Kwon
Journal:  Prostate Int       Date:  2021-04-17

Review 4.  Evaluation and Management of Genitourinary Emergencies in Patients with Cancer.

Authors:  Demis N Lipe; Phillip B Mann; Rodrick Babakhanlou; Maria T Cruz Carreras; A Guido Hita; Monica K Wattana
Journal:  Emerg Med Int       Date:  2021-07-27       Impact factor: 1.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.